Prognostic value of single PET-CT after chemotherapy combined with immunotherapy in patients with non-small cell lung cancer treated with radiotherapy
- VernacularTitle:化学免疫治疗后单次PET-CT对非小细胞肺癌放疗患者的预后预测
- Author:
Zhenghui MA
1
;
Yuqi WU
1
;
Guangqian JI
1
;
Zongmei ZHOU
1
;
Qinfu FENG
1
;
Zefen XIAO
1
;
Jima LYU
1
;
Xin WANG
1
;
Jianyang WANG
1
;
Wenyang LIU
1
;
Lei DENG
1
;
Wenqing WANG
1
;
Nan BI
1
;
Junlin YI
1
;
Tao ZHANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Carcinoma, non-small cell lung; Neoadjuvant chemotherapy combined with immunotherapy; Radiotherapy; Single PET-CT; Survival; Prognosis
- From: Chinese Journal of Radiation Oncology 2025;34(11):1111-1116
- CountryChina
- Language:Chinese
- Abstract: Objective:To evaluate the role of a single PET-CT scan in predicting survival and prognosis in patients with non-small cell lung cancer (NSCLC) who did not undergo surgery but received radiotherapy after neoadjuvant chemotherapy combined with immunotherapy.Methods:A retrospective analysis was conducted on the data of 23 NSCLC patients treated at the Cancer Hospital of the Chinese Academy of Medical Sciences from May 2022 to June 2024. All patients were pathologically confirmed, received neoadjuvant chemotherapy combined with immunotherapy, did not undergo surgery for various reasons, and instead received radiotherapy. Each patient underwent only one PET-CT scan after neoadjuvant chemotherapy combined with immunotherapy and before radiotherapy. According to the maximum standardized uptake value (SUV max) on PET-CT, patients were divided into the low-uptake group (SUV max < 8, n=12) and high-uptake group (SUV max ≥ 8, n=11). Survival analysis was performed using the Kaplan-Meier method with survival curves plotted. Univariate analysis of influencing factors of survival was conducted using the Cox proportional hazards regression model. Clinical characteristics and survival outcomes of the two groups were compared, including progression-free survival (PFS) and overall survival (OS). Results:The 1-year PFS rates were 100% in the low-uptake group, 54.5% in the high-uptake group. This difference was statistically significant ( P=0.007). The 1-year and 2-year OS rates were both 100% in the low-uptake group, the 1-year and 2-year OS rates were both 90.9% in the high-uptake group, with no statistically significant difference ( P=0.394). Univariate Cox analysis identified age as an independent factor affecting PFS. Conclusions:For NSCLC patients who did not undergo surgical resection but received radiotherapy after neoadjuvant chemotherapy combined with immunotherapy, a single PET-CT scan before radiotherapy has potential value in predicting PFS. However, clinical studies with larger sample size and longer follow-up are required to evaluate its predictive value for OS.
